# PET Core

> **NIH NIH U19** · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · 2023 · $1,328,537

## Abstract

PET Core: Summary/Abstract
The ADNI PET Core will continue its overall mission of standardizing PET data acquisition, performing quality
control on all acquired data, preprocessing PET data to provide uniform resolution and formatting, and analyzing
PET data to provide standard readouts that can be used by investigators around the world. Over time, the ADNI
PET core has evolved to meet changing needs and the introduction of new technologies and the plans for ADNI4
represent another stage in this process. The crucial new features of the PET core will include the introduction of
a new -amyloid PET tracer, [18F]NAV4694, so that ADNI4 will make use of 3 PET tracers as we continue use
of [18F]Florbetaben and [18F]Florbetapir. We will also add 2 new tracers for monitoring deposition of pathological
tau forms by adding [18F]MK6240 and [18F]PI2620 to the ongoing use of [18F]Flortaucipir, bringing tau PET tracers
also to 3. As part of operations, we will harmonize all amyloid PET data to the centiloid scale, and develop
methods for the harmonization of tau PET data. All continuing participants will remain on their existing tracers to
ensure high quality longitudinal data, and new participants will be assigned to new tracers based on proximity to
manufacturing sites. Another new feature of ADNI is the introduction of visual reads on all amyloid scans. These
visual reads will be reported back to sites, where they can be returned to participants, and also can be used in
analyses since visual reads have become an integral part of therapeutic trials. In addition, ADNI4 will complete
the “early frames study” (by concluding enrollment and longitudinal scanning), acquiring dynamic PET data for
the 20 min after injection to estimate perfusion effects and model regional cerebral blood flow as a potential
neurodegeneration biomarker. The aims of the Core will be met by a strong administrative component with
continuation of monthly meetings for optimal input into decision making, and by the data management and
processing that includes image quality control and standardization performed at the University of Michigan and
new quality control procedures for PET data analysis. All participants will undergo amyloid and tau PET imaging
every 2 years, and individuals who are amyloid negative will continue to be followed so that we can examine
“conversion” to amyloid positivity, and effects of high subthreshold and rising amyloid and tau levels in nominally
negative individuals. The acquisition of high quality, longitudinal amyloid and tau data will be crucial to testing
hypotheses concerning the validation of plasma -amyloid and tau measurements, cross-sectional and
longitudinal relationships between biomarker and between biomarkers and cognition, and the examination of tau
PET tracers as outcome measures in clinical trials.

## Key facts

- **NIH application ID:** 10704667
- **Project number:** 5U19AG024904-17
- **Recipient organization:** NORTHERN CALIFORNIA INSTITUTE/RES/EDU
- **Principal Investigator:** William J. Jagust
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $1,328,537
- **Award type:** 5
- **Project period:** 2004-09-30 → 2028-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10704667

## Citation

> US National Institutes of Health, RePORTER application 10704667, PET Core (5U19AG024904-17). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10704667. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*